ELK GROVE VILLAGE, Ill., Sept. 26, 2025 /PRNewswire/ -- Orsini, a leader in rare disease pharmacy solutions, has been chosen by Crinetics Pharmaceuticals, Inc., as a specialty pharmacy partner for ...

(RTTNews) - Crinetics Pharmaceuticals Inc. (CRNX) has begun its pivotal Phase 3 trial of Paltusotine in adults with carcinoid syndrome, dubbed CAREFNDR. Carcinoid syndrome affects about 20% of ...

Crinetics (CRNX) Pharmaceuticals announced the U.S. Food and Drug Administration, FDA, accepted its New Drug Application, NDA, for investigational candidate paltusotine for the treatment and long-term ...

Crinetics announced findings from the PATHFNDR-1 trial showing the investigative oral daily drug may provide patients with the rare disease an alternative from recurring injection therapy. This ...

Tuesday, Crinetics Pharmaceuticals Inc CRNX released topline results from PATHFNDR-2, the second of two Phase 3 studies evaluating the efficacy and safety of paltusotine for acromegaly. Acromegaly is ...

Please provide your email address to receive an email when new articles are posted on . Of six adults with acromegaly initiating paltusotine, five had reductions in IGF-I levels. In a post hoc ...

SAN DIEGO, May 15, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced it will present two abstracts at the American Association of Clinical Endocrinology (AACE) ...

(MENAFN- GlobeNewsWire - Nasdaq) Data show that PALSONIFY was well tolerated and IGF-1 levels remained stably controlled during long-term open label extensions of PATHFNDR-1 and PATHFNDR-2 studies ...

"Paltusotine Sales Forecast"The Paltusotine market is poised for significant expansion following FDA approval as the first once-daily oral therapy for acromegaly. Driven by strong physician adoption, ...

SAN DIEGO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the U.S. Food and Drug Administration (FDA) approved PALSONIFY TM (paltusotine) for ...